Developed by Gennova Biopharmaceuticals Ltd, the Pune-based biotechnology company, its interim clinical data of the Phase I were submitted to the Central Drugs Standard Control Organisation (CDSCO) for review.

Dr Sanjay Singh, CEO of Gennova Biopharmaceuticals Ltd said, “After establishing the safety of our mRNA-based COVID-19 vaccine candidate HGCO19 in Phase I clinical trial, Gennova’s focus is to start Phase II/III pivotal clinical trial. In parallel, Gennova is investing in scaling up its manufacturing capacity to cater to the nation's vaccine requirement.

Read more at https://www.indiatoday.in/science/story/covid-19-mrna-vaccine-genno...